Study #2022-0043
67Cu-SARTATE? Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients with High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1/2a Theranostic Clinical Trial
MD Anderson Study Status
Enrolling
Treatment Agent
67Cu-SARTATE, 64Cu-SARTATE
Description
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Study phase:
Physician name:
Douglas Harrison
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.